Monitoring Response to Hypothyroidism Treatment
Initial Monitoring During Dose Titration
- For patients with hypothyroidism, TSH should be monitored every 6-8 weeks while titrating hormone replacement therapy to achieve a TSH within the reference range, then every 6-12 months once adequately treated, as recommended by the American College of Clinical Oncology 1, 2
- Monitor TSH every 6-8 weeks after starting levothyroxine or after any dose change until the TSH level stabilizes within the reference range, according to the American College of Clinical Oncology 1
- FT4 can be used alongside TSH to help interpret ongoing abnormal TSH levels, as TSH may take longer to normalize, as stated by the American College of Clinical Oncology 1
Long-Term Monitoring
- Once adequately treated with a stable dose, repeat TSH testing every 6-12 months or as indicated by a change in symptoms, as recommended by the American College of Clinical Oncology 1, 2
- Development of a low TSH on therapy suggests overtreatment or recovery of thyroid function, and the dose should be reduced or discontinued with close follow-up, according to the American College of Clinical Oncology 2
Special Considerations
Secondary and Tertiary Hypothyroidism
- TSH is not a reliable marker in central hypothyroidism, as stated by the American College of Clinical Oncology 1, 3
Elderly Patients
- For patients older than 70 years and/or frail patients with multiple comorbidities (including cardiac disease), consider more careful monitoring after initiating therapy at a lower starting dose of 25-50 mcg, as recommended by the American College of Clinical Oncology 2